KAAG1 (CN 103492418 A Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar of the anti-KAAG1 antibody described in CN 103492418 A, targeting KAAG1 (Kidney-Associated Antigen 1), a tumor-associated antigen reported to be present on the surface of certain cancer cells with restricted expression in normal tissues. KAAG1 has been described as being expressed across multiple malignancies—such as ovarian cancer, triple-negative breast cancer, and castration-resistant prostate cancer—making it a useful marker/target for studying tumor antigen biology and target expression heterogeneity in oncology models.

CN 103492418 A discloses KAAG1-binding antibodies and antigen-binding fragments proposed for cancer detection/diagnosis and therapeutic delivery concepts (e.g., using the antibody to deliver a therapeutic moiety to KAAG1-expressing cells). This biosimilar provides the antibody component alone, enabling researchers to investigate KAAG1 antigen profiling, antibody binding specificity, and cell-surface target engagement/internalization behavior in controlled systems—supporting early-stage evaluation of KAAG1 as an oncology target and informing design considerations for payload-based modalities (e.g., ADC concepts) without confounding payload cytotoxicity.